AndreaHarzstarkMD

Oncology • San Francisco, CA

Assistant Professor, Medicine, University of California, San Francisco, School of Medicine

Join to view full profile

Dr. Harzstark is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Harzstark's full profile

Already have an account?

Office
1600 Divisadero St
Urologic Oncology 3RD floor Box 1711
San Francisco, CA 94143
Phone+1 415-353-7171

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2005 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2002 - 2005
Stanford University School of MedicineClass of 2002

Certifications & Licensure

CA State Medical License 2004 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy Start of enrollment: 2006 Apr 01
Completed
Phase 1, Phase 2
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2

Publications & Presentations

PubMed

1 citations
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis
European Urology Oncology. 2024-10-01
Choriocarcinoma Syndrome: A Rare Complication's Impact on Metastatic Germ Cell Tumor Outcomes.
Sanjeev Herr, Razmig Garabet, Lillian Tseng, Andrea L Harzstark, Michael P Russin
Cureus. 2024-04-01
26 citations
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Andrea Loehr, Arif Hussain, Akash Patnaik, Alan H Bryce, Daniel Castellano
European Urology. 2023-03-01

Lectures

Identifying predictors of pathologic complete response to neoadjuvant chemotherapy for muscle invasive bladder cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

With Help from Kaiser Permanente, Bladder Cancer CuredJune 28th, 2017